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Background: Recent studies and case reports have shown that recombinant factor VIIa 
(rFVIIa) treatment is effective for reversing coagulopathy and reducing blood transfusion 
requirements in trauma patients with life-threatening hemorrhage. The purpose of this 
study is to evaluate the effect of rFVIIa treatment on clinical outcomes and cost effective-
ness in trauma patients.
Methods: Between January 2007 and December 2010, we reviewed the medical records 
of patients who were treated with rFVIIa (N=18) or without rFVIIa (N=36) for life-threaten-
ing hemorrhage due to multiple traumas at the Emergency Department of Pusan National 
University Hospital in Busan, Korea. We reviewed patient demographics, baseline charac-
teristics, initial vital signs, laboratory test results, and number of units transfused, and then 
analyzed clinical outcomes and 24-hr and 30-day mortality rates. Thromboembolic events 
were monitored in all patients. Transfusion costs and hospital stay costs were also calcu-
lated.
Results: In the rFVIIa-treated group, laboratory test results and clinical outcomes improved, 
and the 24-hr mortality rate decreased compared to that in the untreated group; however, 
30-day mortality rate did not differ between the groups. Thromboembolic events did not 
occur in both groups. Transfusion and hospital stay costs in the rFVIIa-treated group were 
cost effective; however, total treatment costs, including the cost of rFVIIa, were not cost ef-
fective.
Conclusions: In our study, rFVIIa treatment was shown to be helpful as a supplementary 
drug to improve clinical outcomes and reduce the 24-hr mortality rate, transfusion and 
hospital stay costs, and transfusion requirements in trauma patients with life-threatening 
hemorrhage.
Key Words: Recombinant factor VIIa, Multiple trauma, Clinical outcome, Mortality rate, 
Treatment cost
Received: July 29, 2011 
Revision received: September 28, 2011
Accepted: November 7, 2011
Corresponding author: Hyung Hoi Kim
Department of Laboratory Medicine, 
Pusan National University Hospital, 10 
Ami-dong, Seo-gu, Busan 602-739, Korea
Tel: +82-51-240-7414
Fax: +82-51-247-6560
E-mail: hhkim@pusan.ac.kr
*These authors contributed equally to this 
work.
© The Korean Society for Laboratory Medicine.
This is an Open Access article distributed under 
the terms of the Creative Commons Attribution 
Non-Commercial License (http://creativecom-
mons.org/licenses/by-nc/3.0) which permits un-
restricted non-commercial use, distribution, and 
reproduction in any medium, provided the origi-
nal work is properly cited.
INTRODUCTION
Massive blood transfusion is inevitable for multiple trauma pa-
tients with life-threatening hemorrhage. However, numerous 
complications of massive blood transfusion, such as dilutional 
thrombocytopenia, coagulation factor deficiency, disseminated 
intravascular coagulation, hypothermia, acidosis, citrate intoxi-
cation, hyperkalemia, transfusion reactions, and infections can 
occur [1, 2]. In recent years, there have been many studies fo-
cused on reducing the transfusion requirements in multiple 
trauma patients to decrease the risks and complications associ-
ated with massive blood transfusion.
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  Recombinant activated factor VII (rFVIIa; NovoSeven; Novo 
Nordisk Pharmaceuticals, Bagsvaerd, Denmark), a trypsin-like 
serine protease that plays a key role in the blood coagulation 
cascade [3], has also been used to decrease blood transfusion 
requirements in patients with multiple trauma and life-threaten-
ing hemorrhage. Initially, rFVIIa was used in patients with con-
genital or acquired hemophilia along with inhibiting antibodies 
against factor VIII or IX. Currently, rFVIIa is licensed for use in 
hemophiliacs in the USA, Europe, and many other countries 
throughout the world [4].
  In the last few years, rFVIIa has also been used as a universal 
hemostatic agent for the following conditions:congenital factor 
VII deficiencies, platelet disorders, other coagulation factor de-
fects, liver disorders, liver transplantation, surgery, trauma, and 
reversal of anti-coagulation therapy [5]. Kenet et al. reported the 
first successful use of rFVIIa in a 19-yr-old soldier with traumatic 
coagulopathy associated with a rifle injury [6]. Since that time, 
several studies and case reports have shown that the use of   
rFVIIa is effective in reversing coagulopathy and reducing blood 
transfusion requirements in trauma patients with life-threatening 
hemorrhage.
  However, the limited number of studies has not determined 
whether rFVIIa treatment in trauma patients improves clinical 
outcome, reduces mortality, and is cost effective. Therefore, this 
issue is still controversial. Here, we conducted a retrospective 
cohort study of multiple trauma patients with life-threatening 
hemorrhage who received massive transfusions to evaluate the 
effect of rFVIIa treatment on clinical outcomes, mortality rate, 
and cost effectiveness by comparing rFVIIa-treated patients to 
patients not treated with rFVIIa.
METHODS
We reviewed the medical records of all trauma patients who 
were treated in the Emergency Department of Pusan National 
University Hospital in Busan, Korea between January 2007 and 
December 2010 in a retrospective cohort study. This study was 
approved by the Institutional Review Board of our hospital. We 
selected multiple trauma patients with life-threatening hemor-
rhage who were injured in a traffic accident, falling accident, or 
crushing accident, and received ≥8 units of packed red blood 
cells (pRBCs) within the first 24 hr of hospitalization. We ex-
cluded patients with hemophilia or other coagulation disorders 
as well as pediatric and adolescent patients <18 yr of age.
  The use of rFVIIa was indicated by the following 2 criteria: 
massive hemorrhage due to multiple trauma resulting in hemor-
rhagic shock with an initial systolic blood pressure <90 mmHg, 
and increased transfusion requirements due to continuous, life-
threatening hemorrhage. In the Emergency Department of Pu-
san National University Hospital, rFVIIa has been approved for 
use by emergency medicine specialists. Patients who received 
the rFVIIa drug were injected with a single 240 KIU (a 4.8 mg 
vial) dose intravenously after informed consent on the necessity, 
adverse effects, and high cost of the rFVIIa drug. For non-ap-
proved use of rFVIIa, a 240 KIU dose (a 4.8 mg vial) is adminis-
tered to an adult patient weighing 50-100 kg to achieve a 50-100 
µg/kg dose as recommended according to the study by Good-
nough and Shander [7].
  We also selected patients who were not treated with rFVIIa 
from the multiple trauma patients with life-threatening hemor-
rhage who were injured by a traffic accident, falling accident, or 
crushing accident, and received  ≥8 units of pRBCs within the 
first 24 hr of hospitalization. The rFVIIa-untreated patients also 
had massive hemorrhage due to multiple trauma resulting in 
hemorrhagic shock with an initial systolic blood pressure  <90 
mmHg and increased transfusion requirements due to continu-
ous life-threatening hemorrhage. However, they refused the use 
of rFVIIa because of the extremely high price of the rFVIIa drug.
We recorded the time of admission and the time of rFVIIa ad-
ministration to determine the corresponding time interval. We 
eliminated from the analysis those patients who received rFVIIa 
after the first 24 hr of admission. A total of 18 patients who were 
treated with rFVIIa and 36 patients who were not treated with 
rFVIIa were selected for this study. In addition, 12 patients from 
the study by Joo et al. [8] were also included in the rFVIIa-treated 
group in our study.
  We obtained and reviewed the following information from all 
selected patients:gender, age, weight, mechanism of injury, 
bleeding site, injury severity score (ISS), and abbreviated injury 
scale score (AIS). We obtained initial data of body temperature, 
systolic blood pressure, arterial pH, base deficit, and lactic acid 
level, as well as the changes in hemoglobin level, platelet count, 
prothrombin time (PT), and activated partial thromboplastin time 
(aPTT) for all patients.
  The units of pRBCs, fresh frozen plasma (FFP), and platelet 
(PLT) concentrate transfused before and after rFVIIa administra-
tion within the first 24 hr of hospitalization were recorded for the 
rFVIIa-treated patients. We also reviewed the total units of pRBCs, 
FFP, and PLT concentrate transfused during the first 24 hr of 
hospitalization for both the rFVIIa-treated and rFVIIa-untreated 
patients.
  We analyzed the clinical outcomes, including the duration of Koh YR, et al.
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intensive care unit (ICU) stay, the duration of hospital stay, and 
the mortality rate in the first 24 hr and 30 days. The characteris-
tics of the rFVIIa-treated patients who were alive or dead at 30 
days after admission were compared and analyzed. The trans-
fusion costs and hospital stay costs for both the rFVIIa-treated 
and rFVIIa-untreated patients were calculated. The transfusion 
costs were calculated by multiplying the cost of pRBCs, FFP, 
and PLT concentrates per unit by the number of units used. 
The hospital stay costs were calculated by multiplying the cost 
of one admission day at our hospital by the total number of ad-
mission days. Total treatment cost was the sum total of the 
transfusion costs, the hospital stay costs, and the price of the 
rFVIIa drug.
1. Statistical analysis
Administration of rFVIIa was the independent variable. Other 
covariates analyzed included gender, age, mechanism of injury, 
ISS, AIS (head, face, chest, abdomen, extremities, and exter-
nal), initial systolic blood pressure, body temperature, arterial 
pH, base deficit, lactic acid level, hemoglobin level, platelet count, 
PT, aPTT, number of units transfused, ICU stay, hospital stay, 
and mortality rate. All data were analyzed using MedCalc soft-
ware (version 11.5; MedCalc Software, Mariakerke, Belgium). 
Descriptive statistics for variables were expressed as the mean±
SD. The Mann-Whitney U test was used to compare variables 
between the rFVIIa-treated and rFVIIa-untreated patients. A P 
value of <0.05 was considered statistically significant.
RESULTS
A total of 214 patients who sustained multiple trauma were 
treated in the Emergency Department of Pusan National Univer-
sity Hospital between January 2007 and December 2010. Among 
them, 70 patients received ≥8 units of pRBCs within the first 24 
hr of hospitalization. After patients were eliminated by the exclu-
sion criteria described above, 18 patients who were treated with 
rFVIIa and 36 patients who were not treated with rFVIIa were se-
lected for this study. All rFVIIa-treated patients were intrave-
nously injected with 240 KIU (a 4.8 mg vial) of rFVIIa. The time 
interval from hospital admission to rFVIIa administration was an 
average of 3.3 (±2.8) hr.
  Demographics and baseline characteristics of rFVIIa-treated 
and rFVIIa-untreated patients are shown in Table 1. The male:  
female ratio was 2:1 in the 18 rFVIIa-treated, and 3:1 in the 36 
rFVIIa-untreated patients. The mean age of the rFVIIa-treated 
and rFVIIa-untreated patients was 45.9 yr (range, 26-80 yr) and 
48.7 yr (range, 20-79 yr), respectively (P=0.5509). Of the rFVIIa-
treated patients, 9 (50%), 8 (44%), and 1 (6%) sustained trauma 
from traffic accidents, falls, and crushing accidents, respectively, 
and 20 (56%), 14 (39%), and 2 (6%) of the rFVIIa-untreated pa-
tients sustained trauma from traffic accidents, falls, and crush-
ing accidents, respectively.
  Transfusion units before and after rFVIIa administration within 
the first 24 hr of admission in the 18 rFVIIa-treated patients are 
presented in Fig. 1. The number of units transfused within the 
first 24 hr decreased significantly after rFVIIa administration, and 
before vs. after rFVIIa administration, the number of unit (mean
±SD) was as follows:pRBCs 11.1±3.9 vs. 3.2±2.8, P<0.0001; 
FFP 9.8±5.1 vs. 2.9±2.4, P<0.0001; and PLT concentrate 6.4
±6.8 vs. 1.2±2.4, P=0.0085. The average time interval from 
hospital admission to rFVIIa administration in the rFVIIa-treated 
patients was 3.3 hr. In contrast, the number of transfusion units 
used in the 36 rFVIIa-untreated patients within the first 24 hr 
before vs. after 3.3 hr of admission did not differ significantly; 
Table 1. Demographics and initial laboratory results of the rFVIIa-
treated and rFVIIa-untreated groups
rFVIIa-treated rFVIIa-untreated
P value
(N=18) (N=36)
Age (yr) 45.9 (±16.4) 48.7 (±16.7) 0.5509
Weight (kg) 59.6 (±8.9) 61.1 (±9.9) 0.6576
ISS 30.7 (±8.3) 29.3 (±5.2) 0.4002
Head AIS 1.5 (±1.0) 1.6 (±1.1) 0.8209
Face AIS 0.7 (±1.1) 0.9 (±1.3) 0.6138
Chest AIS 2.1 (±1.7) 1.8 (±1.4) 0.4453
Abdomen AIS 2.2 (±1.3) 1.4 (±1.4) 0.0402
Extremity AIS 3.7 (±1.0) 3.9 (±0.6) 0.5890
External AIS 0.1 (±0.2) 0.1 (±0.3) 0.7425
Body temperature (°C) 35.9 (±0.5) 36.2 (±0.5) 0.0201
Systolic blood pressure 
  (mmHg)
71.4 (±17.5) 82.8 (±15.8) 0.0175
Arterial pH 7.232 (±0.1) 7.301 (±0.2) 0.0405
Base deficit 10.9 (±4.8) 7.7 (±5.9) 0.0459
Lactic acid (mmol/L) 7.1 (±3.6) 5.0 (±3.4) 0.0442
Hemoglobin (g/dL) 8.3 (±2.3) 10.1 (±3.2) 0.0752
Platelet count (×10
3/µL) 88.9 (±49.7) 181.7 (±98.4) 0.0018
PT (sec) 24.6 (±20.4) 15.1 (±4.1) 0.0058
aPTT (sec) 74.8 (±46.5) 47.5 (±32.5) 0.0022
The Mann-Whitney U test was used to calculate P values. The data shown 
are the mean (±SD).
Abbreviations: rFVIIa, recombinant activated factor VII; ISS, injury severity 
score; AIS, abbreviated injury scale score; PT, prothrombin time; aPTT, acti-
vated partial thromboplastin time.Koh YR, et al.
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pRBCs 9.4±3.6 vs. 10.2±4.9, P=0.4115; FFP 6.7±3.0 vs. 8.3±
5.2, P=0.1208; and PLT concentrate 4.9±4.3 vs. 6.6±6.7, P= 
0.2052.
  The number of transfusion units used within the first 24 hr of 
admission and during the entire hospital stay is shown in Table 
2. The data revealed that rFVIIa-treated patients required fewer 
units of pRBCs and FFP than rFVIIa-untreated patients. The 
number of PLT concentrate units transfused did not differ sig-
nificantly between the 2 groups in the independent samples t 
test. However, the number of PLT concentrate units transfused 
was significantly reduced in a multiple regression analysis (P< 
0.001).
  Changes in the mean value of hemoglobin, platelet count, PT, 
and aPTT after rFVIIa administration in the rFVIIa-treated group 
and those within the first 24 hr of admission in the rFVIIa-un-
treated group are shown Fig. 2. Although hemoglobin levels in 
the rFVIIa-treated group increased until 3 hr after rFVIIa admin-
istration, those in the rFVIIa-untreated group decreased. Platelet 
counts decreased in both groups after 24 hr of admission; how-
ever, the platelet count decrease in the rFVIIa-treated group was 
less prominent than that in the rFVIIa-untreated group. The PT 
and aPTT values of the rFVIIa-untreated group were prolonged 
for the first 3 hr, whereas the PT and aPTT values of the rFVIIa-
treated group decreased to the normal range until 6 hr after rFVIIa 
administration.
  Clinical outcomes are shown in Table 3. In rFVIIa-treated group, 
1 patient died within 24 hr due to hypovolemic shock, while 3 
patients died due to hypovolemic shock and 1 from multiple or-
gan failure within 30 days. In the rFVIIa-untreated group, 2 pa-
tients died due to hypovolemic shock, 1 from multiple organ 
failure, and 1 from severe lung contusion within 24 hr, while 3 
patients died due to hypovolemic shock, 2 from septic shock, 
and 1 from chronic renal failure within 30 days.
  Known fatal complications of the rFVIIa drug, including throm-
boembolic events such as acute myocardial infarction or cere-
brovascular infarction, did not occur in the rFVIIa-treated group. 
Thromboembolic events also did not occur in the rFVIIa-untreated 
group.
  Transfusion costs in the rFVIIa-treated and rFVIIa-untreated 
groups were 2,174,217 won and 3,125,246 won, respectively 
(P=0.0084); total hospital stay costs were 2,218,275 won and 
5,478,900 won, respectively (P=0.0017); and total treatment 
costs, including the cost of the rFVIIa drug, were 8,807,692 won 
and 8,604,146 won, respectively (P=0.5571). Therefore, rFVIIa 
treatment could reduce transfusion costs and hospital stay costs; 
however, the total treatment cost, including the price of rFVIIa 
drug, was not cost effective.
  We compared the characteristics of the rFVIIa-treated patients 
who were alive 30 days after admission to those of the rFVIIa-
treated patients who were deceased (Table 4). As shown in Ta-
ble 4, older age, lower initial systolic blood pressure, more acidic 
arterial pH, higher lactic acid level, prolonged PT and aPTT val-
ues, and massive transfusion of pRBCs and FFP were statisti-
cally significant prognostic factors for worse survival in multiple 
trauma patients with life-threatening hemorrhage.
DISCUSSION
Since the first report on the successful use of rFVIIa by Kenet et 
Fig. 1. Transfusion volume (units) of pRBCs (P<0.0001), FFP (P< 
0.0001), and PLT concentrate (P=0.0085) before (pre) and after 
(post) rFVIIa administration within the first 24 hr of hospital admis-
sion in the 18 rFVIIa-treated patients. Data are presented as box 
plots with median lines.
Abbreviations: RBC, red blood cells; FFP, fresh frozen plasma; PLT, platelet 
concentrates; rFVIIa, recombinant activated factor VII.
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Table 2. Transfusion units within the first 24 hours and during the 
entire hospital stay
rFVIIa-treated
(N=18)
rFVIIa-untreated
(N=36) P value
Within the first 24 hr
  pRBCs (units) 14.2 (±5.9) 19.6 (±7.1) 0.0052
  FFP (units) 11.0 (±7.9) 14.9 (±7.1) 0.0254
  PLT (units) 7.5 (±8.9) 11.3 (±9.9) 0.1334
During the entire hospital stay
  pRBCs (units) 19.8 (±7.8) 26.7 (±11.2) 0.0113
  FFP (units) 14.4 (±10.2) 21.8 (±13.5) 0.0250
  PLT (units) 16.6 (±18.2) 24.6 (±24.1) 0.1520
The Mann-Whitney U test was used to calculate P values. The data shown 
are the mean (±SD).
Abbreviations: rFVIIa, recombinant activated factor VII; pRBCs, packed red 
blood cells; FFP, fresh frozen plasma; PLT, platelet concentrate.Koh YR, et al.
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al. [6], many studies have reported on the use of rFVIIa in pa-
tients with profuse bleeding due to severe trauma. Martinowitz 
et al. reported that the use of rFVIIa led to cessation of diffuse 
bleeding and decreased the blood transfusion requirement to 2 
units of pRBCs with reduced PT and aPTT in 7 multiple-trans-
fused trauma patients with life-threatening hemorrhage [9]. Dut-
ton et al. reported 5 cases involving trauma patients treated with 
rFVIIa for control of hemorrhage in retrospective case reviews, 
and suggested that the use of rFVIIa effectively controlled hem-
orrhage in trauma patients [10]. Mayo et al. described 13 pa-
tients with life-threatening hemorrhage who experienced a re-
duction or cessation of bleeding after rFVIIa infusion [11].
  Our study also showed that the number of pRBC and FFP 
units transfused was reduced after rFVIIa administration in the 
rFVIIa-treated group; the rFVIIa-treated group required approxi-
mately 4-8 fewer units than the rFVIIa-untreated group. There 
was no statistically significant difference in the number of PLT 
concentrate units transfused between the 2 groups by the inde-
pendent samples t test; however, multiple regression analysis 
revealed that the number of PLT concentrate units transfused 
was significantly reduced in the rFVIIa-treated patients com-
pared to the rFVIIa-untreated patients (P<0.001).
  In order to aid physicians, Goodnough et al. suggested hospi-
tal-based transfusion service guideline policies for rFVIIa therapy 
[12]. Loudon et al. determined that intervention with rFVIIa after 
transfusion of 14 units of pRBCs is cost effective due to conser-
Table 3. Clinical outcomes of the rFVIIa-treated and rFVIIa-untreat-
ed groups
rFVIIa-treated
(N=18)
rFVIIa-untreated
(N=36) P value
ICU stay (days) 10.5 (±7.8) 27.0 (±28.0) 0.0325
Hospital stay (days) 27.1 (±37.9) 65.1 (±48.7) 0.0032
24-hr mortality rate (N) 5.6% (1) 11.1% (4) 0.5447
30-day mortality rate (N) 27.8% (5) 27.8% (10) 1.0000
The Mann-Whitney U test was used to calculate P values. The data shown 
are the mean (±SD).
Abbreviations: rFVIIa, recombinant activated factor VII; ICU, intensive care 
unit.
Fig. 2. Changes in mean (A) hemoglobin, (B) platelet count, (C) PT, and (D) aPTT after rFVIIa administration in the rFVIIa-treated group 
(N=18, straight lines) and within the first 24 hr of admission in the rFVIIa-untreated group (N=36, dotted lines).
Abbreviations: PT, prothrombin time; aPTT, activated partial thromboplastin time; rFVIIa, recombinant activated factor VII.
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vation of blood components and a reduction in the duration of 
ICU stay [13]. Grounds et al. assessed the efficacy and safety of 
rFVIIa in 45 patients with massive bleeding requiring >14 units 
of pRBCs. They concluded that the use of rFVIIa reduced blood 
loss, transfusion requirements, and the mortality rate [14]. Rizoli 
et al. performed a retrospective cohort study of 38 rFVIIa-treated 
patients and 204 rFVIIa-untreated patients, and showed that   
rFVIIa might improve early survival of trauma patients with life-
threatening hemorrhage [15].
  In our study, we selected patients who received  ≥8 units of 
pRBCs within the first 24 hr of hospitalization, and showed that 
the use of rFVIIa improved clinical outcomes, reduced the dura-
tion of both the ICU and total hospital stays, and was cost effec-
tive in massive bleeding patients who required ≥8 units of pRBCs.
  Cameron et al. reviewed the Australian and New Zealand Hae-
mostasis Registry databases and reported that rFVIIa decreased 
or stopped bleeding in 59% of cases for which efficacy was re-
ported. Body temperature, arterial pH, and ISS were shown to 
contribute to the best model for prediction of mortality [16]. In 
our study, we recognized that older age, lower initial systolic 
blood pressure, more acidic arterial pH, higher lactic acid level, 
prolonged PT and aPTT values, and massive transfusion of 
pRBCs and FFP were statistically significant prognostic factors 
of worse survival in multiple trauma patients with life-threatening 
hemorrhage.
  Boffard et al. and Rizoli et al. conducted 2 randomized, pla-
cebo-controlled, double-blind clinical trials to evaluate the effi-
cacy and safety of rFVIIa in trauma patients with severe bleeding. 
The number of pRBCs, FFP, and PLT concentrate units trans-
fused was significantly reduced in the rFVIIa-treated group com-
pared to the placebo group, and the need for massive transfu-
sion was reduced. Moreover, trends toward a reduction in mor-
tality and critical complications were observed [17, 18].
  Martinowitz and Michaelson established a Multidisciplinary 
Task Force and published guidelines for the use of rFVIIa in 
cases of uncontrolled bleeding. They recommended that an ini-
tial dose of 200 µg/kg of rFVIIa, followed by 2 100 µg/kg doses 
administered 1 and 3 hr after the first dose may reduce RBC 
transfusion requirements, the need for massive transfusion, and 
the incidence of respiratory failure in patients with blunt trauma 
[19]. A European committee also developed consensus guide-
lines for use of rFVIIa in patients with life-threatening hemor-
rhage based on a review of MEDLINE, EMBASE, and Cochrane 
databases [20]. In 2 placebo-controlled pharmacokinetic studies 
of rFVIIa in trauma patients, the mean clearance of rFVIIa was 
40 mL·kg
-1·h
-1 and the terminal half-life was 2.4 hr. Increased 
intra- and inter-patient variability occurred in the volume of dis-
tribution and clearance of rFVIIa, and this increased variability 
was mainly related to transfusion requirements, blood loss, and 
bleeding rate [21].
  However, whether or not rFVIIa treatment in patients with mul-
tiple trauma improves clinical outcomes and is cost effective is 
still a controversial issue. Yank et al. evaluated the benefits and 
harms of rFVIIa use for 5 off-label indications, including trauma, 
by reviewing and analyzing 10 databases. They concluded that 
there was no difference in mortality from trauma; however, the 
risk for thromboembolism did not increase, but the risk for acute 
respiratory distress syndrome decreased [22]. Lin et al. searched 
several databases up to 2009 and also concluded that the effec-
tiveness of rFVIIa remains unproven [23].
  Joo et al. [8] first reported the off-label use of rFVIIa in 15 
Table 4. Characteristics, initial vital signs, and initial laboratory re-
sults at admission, and units transfused for rFVIIa-treated patients 
who were alive vs. dead 30 days after admission
Living rFVIIa-
treated patients
(N=13)
Dead rFVIIa- 
treated patients
(N=5)
P value
Age (yr) 40.2 (±13.3) 60.6 (±15.5) 0.0205
ISS 29.4 (±9.2) 34.2 (±4.3) 0.3430
Body temperature (°C) 36.1 (±0.1) 35.6 (±0.9) 0.1189
Systolic blood pressure (mmHg) 77.3 (±16.9) 56.0 (±5.5) 0.0114
Arterial pH 7.3 (±0.1) 7.1 (±0.1) 0.0018
Base deficit 9.4 (±4.4) 14.2 (± 4.4) 0.0791
Lactic acid (mmol/L) 5.0 (±1.9) 11.3 (±2.2) 0.0048
Hemoglobin (g/dL) 9.0 (±2.2) 6.5 (±1.7) 0.0682
Platelet count (×10
3/µL) 96.5 (±52.3) 69.2 (±40.3) 0.4304
PT (s) 23.4 (±23.5) 27.8 (±9.3) 0.0341
aPTT (s) 50.4 (±14.2) 138.2 (±40.4) 0.0014
Within the first 24 hr
  pRBCs (units) 12.0 (±4.7) 20.0 (±5.1) 0.0118
  FFP (units) 8.9 (±7.1) 16.4 (±8.0) 0.0542
  PLT (units) 5.9 (±7.4) 11.6 (±12.0) 0.1730
Entire hospital stay
  pRBCs (units) 17.0 (±5.6) 27.2 (±8.4) 0.0263
  FFP (units) 11.5 (±8.3) 22.2 (±11.5) 0.0233
  PLT (units) 11.8 (±11.0) 29.2 (±27.7) 0.1248
The Mann-Whitney U test was used to calculate P values. The data shown 
are the mean (±SD).
Abbreviations: rFVIIa, recombinant activated factor VII; ISS, injury severity 
score; PT, prothrombin time; aPTT, activated partial thromboplastin time; 
pRBCs, packed red blood cells; FFP, fresh frozen plasma; PLT, platelet con-
centrates.Koh YR, et al.
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multiple trauma patients in Korea. They compared the units of 
pRBCs and FFP transfused per hr before and 6 hr after rFVIIa 
administration, vital signs (systolic blood pressure and heart 
rate) before and after rFVIIa administration, and changes in PT 
and aPTT before and 30, 60, and 180 min after rFVIIa adminis-
tration. They concluded that the units of pRBCs and FFP trans-
fused per hour were significantly reduced and PT and aPTT 
were significantly corrected with no difference in vital signs. In 
our study, the PT and aPTT of the rFVIIa-treated group were 
corrected until 6 hr after rFVIIa administration.
  There were significant differences between the study by Joo 
et al. [8] and our study; we selected 18 rFVIIa-treated patients 
(including 12 patients in the study by Joo et al.) and 36 rFVIIa-
untreated patients from all multiple trauma patients using our 
own inclusion and exclusion criteria; we compared the total 
transfused units (including PLT concentrate) within the first 24 
hr of admission and during the entire hospital stay between the 
2 groups; we also analyzed the clinical outcomes (including the 
duration of the ICU and total hospital stays); we also examined 
the mortality rate within the first 24 hr and 30 days; Transfusion 
costs, hospital stay costs, and total treatment costs were calcu-
lated and compared between the 2 groups.
  The major adverse effects of rFVIIa, including thromboem-
bolic events such as acute myocardial infarction or cerebrovas-
cular infarction, did not occur in the rFVIIa-treated patients or 
the rFVIIa-untreated patients.
  Treatment with rFVIIa could significantly reduce transfusion 
costs and hospital stay costs; however, the total treatment costs, 
including the price of the rFVIIa drug, were not cost-effective. 
However, we presume that in the future the total treatment cost 
will be cost-effective if the Food and Drug Administration (FDA) 
approves the use of rFVIIa for trauma patients and the price of 
rFVIIa drug is reduced.
  In conclusion, the number of units transfused was significantly 
reduced after rFVIIa administration within the first 24 hr of ad-
mission in the rFVIIa-treated patients, while the number of units 
transfused was not significantly reduced in the rFVIIa-untreated 
patients. The rFVIIa-treated patients required approximately 4-8 
fewer units of pRBCs and FFP than the rFVIIa-untreated pa-
tients. The number of PLT concentrate units transfused did not 
differ significantly between the 2 groups by the independent 
samples t test; however, the number of PLT concentrate units 
transfused was significantly reduced in the rFVIIa-treated pa-
tients compared to the rFVIIa-untreated patients by multiple re-
gression analysis. Treatment with rFVIIa led to significantly bet-
ter clinical outcomes and a reduced 24-hr mortality rate without 
a reduction in the 30-day mortality rate. Treatment with rFVIIa 
was cost-effective for transfusion costs and hospital stay costs; 
however, the total treatment costs, including the price of the rF-
VIIa drug, were not cost-effective. Therefore, our study showed 
that the use of rFVIIa could be helpful as a supplementary ther-
apy to improve clinical outcomes, reduce the 24-hr mortality 
rate, reduce transfusion costs and hospital stay costs, and de-
crease blood transfusion requirements in multiple trauma pa-
tients with life-threatening hemorrhage.
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